Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database by Jackie Imrie et al.
RESEARCH ARTICLE Open Access
Observational cohort study of the natural
history of Niemann-Pick disease type C in
the UK: a 5-year update from the UK
clinical database
Jackie Imrie1*, Lesley Heptinstall2, Stephen Knight2 and Kate Strong3
Abstract
Background: Niemann-Pick disease type C (NP-C) is a rare neurovisceral lipid storage disorder characterised by
progressive, disabling neurological symptoms and premature death in most patients. During the last decade,
national cohort studies have accrued a great deal of data on the symptomatology and natural history of NP-C.
Methods: In an observational cohort study, we present a substantial update based on the clinical presentation and
follow-up of all known UK-based patients with a confirmed diagnosis of NP-C who have been tracked on an electronic
database at the Department of Genetic Medicine, University of Manchester, UK. Patients were stratified according to
accepted age-at-neurological-onset categories. Data on patients’ clinical signs and symptoms, medical history and
genetic studies are summarised using descriptive methods.
Results: A total of 146 patients with NP-C were included, representing the full known UK NP-C cohort, as observed
from database information between 1999 and the end of 2011: 72 patients (49 %) were alive at the end of the
observation period. Among a total of 116 patients (79 %) who possessed at least one identified, disease-causing NP-C
gene mutation, 114 (98 %) had NPC1 and two (2 %) had NPC2 mutations. Overall, 53/194 (27 %) identified mutations
were novel. Six patients (4 %) had an early, non-neurological neonatal onset form of NP-C. The numbers (%) of patients
with accepted age-at-neurological onset forms were: 8 (5 %) early-infantile onset, 51 (35 %) late-infantile onset, 42 (29 %)
juvenile onset, and 25 (17 %) adolescent/adult onset. Fourteen patients diagnosed based on visceral symptoms and/or
sibling history, confirmed in most cases by genetic analysis, did not have any neurological manifestations at last follow up
(11 patients with mean [SD] age at last follow up 2.5 [1.8] years: 3 with mean [SD] age at death 20.8 [15.9] years). A total
of 51 patients (35 %) received miglustat therapy. The mean (SD) overall treatment duration up to the end of the
observation period was 2.6 (2.3) years.
Conclusions: This UK cohort is the largest national NP-C cohort reported to date, and confirms the wide phenotypic
variability of the disease, as reported in other countries. Further analyses are required to assess the impact of miglustat
therapy on neurological disease progression.
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Background
Niemann-Pick disease type C (NP-C) is a rare neurovisc-
eral lipid storage disorder characterised by progressive,
disabling neurological symptoms and premature death in
most patients [1–3]. It is caused by autosomal recessive
inheritance of mutations in either of two genes (NPC1
and NPC2), and has been estimated to affect one case in
every 100,000–120,000 live births [1, 2, 4].
The clinical presentation of NP-C is highly heteroge-
neous, necessitating a multidisciplinary diagnostic process
that takes into account clinical assessments, histological
and electron microscopic tests, and biochemical and mo-
lecular genetic laboratory studies [1, 5]. Clinical work-up
requires detection and recognition of numerous non-
specific systemic and neurological signs and symptoms.
While ancillary testing helps to narrow the differential
diagnosis, final confirmation of NP-C requires demonstra-
tion of characteristic intralysosomal accumulation of
unesterified cholesterol (based on filipin staining in cul-
tured skin fibroblasts) and/or the identification of one or
more disease-causing mutations in either the NPC1 or
NPC2 genes [1, 2]. The demonstration of abnormal chol-
esterol homeostasis with impaired low-density lipoprotein
(LDL)-induced cholesterol esterification can also provide
supportive data in cases with an uncertain biochemical
phenotype, but is rarely performed now [5, 6]. Newer
screening and diagnostic tools have recently been devel-
oped. The NP-C suspicion index (SI) allows more rapid
detection of patients who warrant further testing for NP-C
[7–9]. Laboratory measurements of plasma oxysterols (par-
ticularly cholestane-3β,5α,6β-triol and 7-ketocholesterol)
[10–12], and certain sphingolipids such as lyso-sphingosine
[13, 14], have shown promise in allowing more rapid diag-
nosis in patients with suggestive clinical signs and symp-
toms. The increasing application of these newer measures
is expected to increase the efficiency of diagnosis in NP-C.
Previous studies in cohorts of NP-C patients from
France, Spain, Portugal and the USA have accrued data
describing the biochemical and clinical phenotypes, genet-
ics and natural history of NP-C [15–17]. NP-C has histor-
ically been considered a childhood-onset disease, but
patients with late-onset symptoms are increasingly being
detected due to the wider application of biochemical and
genetic diagnostic techniques. In 2007, a retrospective
case note review documented clinical signs and symptoms
and subsequent disease course based on 94 NP-C patients
diagnosed in the UK between 1999 and 2006 [15]. Data
were available from approximately even numbers of
patients with neonatal-onset (n = 33), childhood-onset
(n = 31) and adolescent/adult-onset disease (n = 30),
and a detection rate of 4–5 new cases per year between
1990 and 1999 was reported [15].
Major efforts have been made in the last decade to fur-
ther consolidate clinical data from all known NP-C
patients diagnosed and managed in the UK. This report
provides an update of information from the UK NP-C
database based on data collected between 1999 and the
end of 2011, including a further 52 patients since the
previous report in 2006 [15].
Methods
The UK NP-C database
We reviewed retrospective data for all UK-based patients
with NP-C whose details were stored in a database main-
tained by the Niemann-Pick Disease Clinical Nurse
Specialist at the Department of Genetic Medicine, Univer-
sity of Manchester, UK. All data were collected during
clinical visits forming part of ongoing long-term care. The
database contained information from all UK patients with
a diagnosis of NP-C that had been confirmed using filipin
staining, causal gene mutation analysis and/or esterifica-
tion studies between 1999 and the end of 2011 (data cut-
off). All patients were either referred or self-referred to
the Nurse Specialist or Support Group.
Diagnostic information
Laboratory diagnostic data for all patients are included
from at least one of three laboratories in the UK and/or
France that provide the required specialised testing. Diag-
nostic Laboratories in the UK and Lyon, France were in-
volved independently in submitting information on cases
they diagnosed to the database.
In general diagnostic information included findings
from skin biopsy analyses (filipin staining and cholesterol
esterification assays) from all UK patients with: 1) clinical
symptoms suggestive of NP-C and; 2) raised plasma chito-
triosidase (routinely checked alongside white-cell enzymes
if laboratory analyses hinted at a possible lysosomal stor-
age disease). NPC1 gene sequencing analyses were con-
ducted in all patients with positive filipin staining and/or
cholesterol esterification findings, and some sibling cases.
Patients in whom NPC1 mutations were not identified, or
on whom complementation studies have not been per-
formed, underwent further investigations and NPC2 gene
sequencing.
Clinical manifestations
During the observation period, information on key signs
and symptoms of NP-C were recorded up to the last clin-
ical follow up (i.e., last clinic visit and/or update of med-
ical records in the database) in line with international
guidelines for the diagnostic assessment and follow-up of
the disease [1]. The following data types were included
whenever possible: oculomotor signs (e.g. vertical supra-
nuclear gaze palsy [VSGP]), neurological manifestations
(e.g., cerebellar signs [ataxia, dysarthria, dysphagia, dyskin-
esia], seizures/cataplexy); spasticity; childhood develop-
mental status (e.g. psychomotor delay and/or regression,
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learning disabilities); cognitive loss/problems, psychiatric
abnormalities (e.g., psychosis, behavioural abnormalities);
and systemic symptoms (e.g., hepatosplenomegaly, lung
disease or neonatal cholestatic disease). Information on
miglustat therapy was also included, where available, for
all treated patients.
Ethical data reporting
All information was accessed in accordance with applic-
able laws and ethical requirements for the study period
concerned, and all study procedures, including informed
consent for molecular genetic analyses, were conducted in
line with ethical standards of the responsible institutional
ethics committees and the Helsinki Declaration (1975)
and subsequent revisions. All patients and/or their kin
provided written informed consent for publication of indi-
vidual clinical details, as presented in this report. Data re-
ported previously for patients included in this cohort,
based on publications by Lachmann et al. [18], Patterson
et al. [19], and Patterson et al. [20], are identified where
relevant.
Data analysis
In recognition of international guidelines for the manage-
ment of NP-C, patients are assessed based on neonatal
presentation of NP-C (characterised mainly by systemic
symptoms [splenomegaly, hepatomegaly, neonatal chole-
static disease and liver failure], and hereafter referred to as
the ‘neonatal’ form), and as per accepted age subgroups
based on onset of neurological manifestations (i.e., early
infantile- [<2 years], late infantile- [2 to <6 years], juvenile-
[6–15 years] and adolescent/adult-onset [>15 years]).
Patients with a confirmed diagnosis but, as yet, no neuro-
logical symptoms, were also included in a ‘non neuro-
logical’ category.
All data analyses were exploratory in nature, and no
statistical analyses of differences between patient sub-
groups were performed. Data are presented using
descriptive statistics (mean, SD, median and range for
continuous variables, and n (%) for categorical values).
Patients for whom no numerical data values were avail-
able were treated as having ‘missing values’.
Results
Overall cohort characteristics
This UK cohort comprised a total of 146 NP-C patients
born between 1954 and 2009, among whom 77 (53 %)
were female and 69 (47 %) male. Patient demographics
and general characteristics per patient subgroup are
summarised in Table 1. Among a total of 112 patients
(77 %) who possessed at least one identified, disease-
causing NP-C gene mutation, 110 (98 %) had NPC1 mu-
tations and two (2 %) had NPC2 mutations. In patients
where genetic analyses did not reveal any known or
identifiable novel mutations, diagnoses were based on











Gender, n (%) female 3 (50) 7 (88) 28 (55) 25 (60) 10 (40)
Age, years:
At neurological onset
na – 8 50 40 18
Mean (SD) – 1.1 (0.7) 4.1 (1.2) 9.4 (2.6) 24.2 (8.8)
At diagnosis
na 4c 7c 49 39 24
Mean (SD) 0.1 (0.1) 1.3 (1.5) 4.6 (5.5) 11.5 (7.4) 29.3 (9.3)
At last follow upb
na – – 19 21 17
Mean (SD) – – 11.6 (8.9) 20.2 (9.0) 39.5 (9.2)
At death
na 6 8 30 19 8
Mean (SD) 0.19 (0.22) 5.6 (2.0) 13.4 (6.7) 25.9 (8.9) 33.7 (6.2)
Number (%)d with NP-C
genetic information
1 (17) 8 (100) 41 (80) 36 (86) 16 (64)
Number (%)d treated with
miglustat
– 2 (25) 17 (33) 20 (48) 12 (48)
aNumber of patients with available data; blast follow up (data cut-off at end-2011) in living patients only; cage at diagnosis not relevant for two neonatal patients
and one early-infantile patient who were diagnosed post-mortem; dpercentages calculated relative to total number of patients per treatment subgroup
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filipin staining and ancillary methods combined with
clinical examination findings and medical history.
Six patients (4 %) had the visceral neonatal form of NP-
C. The numbers (%) of patients per accepted age-at-
neurological onset category were: early-infantile onset (n =
8 [5 %]), late-infantile onset (n = 51 [n = 35 %]), juvenile
onset (n = 42 [29 %]); and adolescent/adult onset (n = 25
[17 %]). A total of 14 patients (10 %), most of whom were
detected due to early visceral symptoms and three of whom
had a sibling history of NP-C, had no neurological symp-
toms and are categorised herein as having non-neurological
disease.
The overall mean (SD; range) ages at neurological onset
and diagnosis were 8.8 (8.1; 0–40) years and 10.4 (11.5; 0–
49.5) years, respectively. In general, age at diagnosis tended
to increase in line with age at onset of neurological manifes-
tations (Table 1): NP-C was diagnosed most quickly among
patients with infantile onset, with the greatest delays to diag-
nosis recorded among patients with adolescent/adult onset.
A total of 43 patients (29 %) were siblings who were also af-
fected by NP-C. Based on all patients with available data,
the mean time period between neurological disease onset
and diagnosis was 1.73 (5.80) years, while this period among
the sibling subgroup was 1.25 (4.75) years. In many cases,
confirmation of a diagnosis of NP-C in one sibling led to a
more rapid diagnosis in either younger or older siblings.
Overall, 72/146 (49 %) patients were alive at data cut-
off. Among patients with available data, the mean age at
last follow up (i.e., the latest clinical assessment before
data cut-off at the end of 2011) ranged from 11.6 years in
the late-infantile onset subgroup to 39.5 years in the ado-
lescent/adult-onset subgroup. Mean ages at death among
the age-at-onset subgroups ranged from 0.19 years among
neonatal patients to 33.7 years in the adolescent/adult-on-
set subgroup. In non-neurological NP-C patients , the
mean age at last follow-up among 11 living patients was
2.5 years (range 0.5–6.1). The mean age at death among
three non-neurological patients who died was 20.8 (15.9)
years (range 4.9–36.7).
Neurological and psychiatric manifestations: overall cohort
The large majority of patients had at least one neuro-
logical manifestation commonly associated with NP-C at
last follow up. A total of 19 patients (13 %) had no re-
corded manifestations, five of whom had the neonatal
form of the disease.
Figure 1 summarises the prevalence of individual neuro-
logical symptoms per age at onset subgroup. Overall, de-
velopmental delay (during childhood) and/or cognitive
deterioration were recorded in the greatest proportion of
patients up to last follow up (in 119/146 patients [82 %]).
In order of incidence, other common neurological signs
were: ataxia (in 110 patients [76 %]), VSGP (103 patients
[71 %]), dysarthria (99 patients [68 %]), dysphagia (93 pa-
tients [64 %]) and seizures/cataplexy (72 patients [50 %]).
Psychiatric disturbances were recorded in a total of 17
(12 %) patients. As could be expected, all cases in whom
psychiatric disturbances were recorded were in the
juvenile-onset or adolescent/adult-onset subgroups (inci-
dence per subgroup 8/42 patients [19 %] and 9/25 pa-
tients [36 %], respectively).
Visceral symptoms: overall cohort
Visceral symptoms of NP-C were recorded most frequently
in patients with the neonatal visceral form of NP-C and in























Neonatal (n = 6)
Early infantile (n = 8)
Late infantile (n = 51)
Juvenile (n = 42)
Adolescent/adult (n = 25)
Fig. 1 Occurrence of neurological and psychiatric manifestations per patient subgroup Percentages calculated based on numbers of patients with
available data
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and least frequently among adolescent/adult-onset patients
(Fig. 2). Prolonged neonatal jaundice with or without neo-
natal liver disease was by far the most common visceral
symptom, occurring in all neonatal onset, 6/8 (75 %) early-
infantile onset, 29/51 (57 %) late-infantile onset, and 14/42
(33 %) juvenile-onset patients. Only one adolescent/adult-
onset patient had a recorded history of neonatal jaundice.
Organomegaly (hepatosplenomegaly in most cases) also
tended to occur less and less frequently as age at neuro-
logical onset increased. All patients in whom no neuro-
logical manifestations have yet been recorded had a history
of at least one visceral symptom, most commonly pro-
longed neonatal jaundice (in 5/14 [36 %] patients).
Clinical symptomatology and outcomes in age-at-onset
subgroups
Neonatal onset patients
All six patients with the neonatal form of NP-C had liver
disease at or soon after birth (mean [SD] age 0.19 [0.22]
years), with organomegaly also apparent in four cases and
foetal ascites present in two (Table 2). Hepatosplenome-
galy was also recorded in four cases. Patients with the se-
vere neonatal-onset form of NP-C have been reported in
other national cohorts to have a short lifespan [2, 16], and
the same was true in this UK cohort. Two cases were still-
born and the other four died within 1–7 months of birth.
Liver disease was the most frequently recorded cause of
death (three patients), and one patient died due to failure
to thrive and chest infection. One patient (patient 1) had a
record of developmental delay from birth.
Early-infantile onset patients
All but one of the early-infantile onset patients were fe-
male (Table 3). The mean (SD; range) age at onset of
neurological manifestations in this subgroup was 1.1 (0.7;
0–2.0) years. Overall, the mean (SD) time between onset
of neurological manifestations and diagnosis was 0.26
(1.49) years, with diagnostic testing commenced based on
recognition of visceral symptoms in four patients.
The mean (SD) age at death was 5.6 (2.0) years. The
most common recorded cause of death (7/8 cases [88 %])
was ‘NP-C’, reflecting a gradual and in some cases rapid
deterioration, with eventual loss of all skills and bodily
functions with no one apparent causative factor. However,
the recorded causes of death could reflect the way death
certificates are completed in the UK, where the primary
disease is often stated as the causative factor.
A total of 6/8 patients (75 %) exhibited both prolonged
neonatal jaundice and hepatosplenomegaly (Fig. 2). One
patient (patient 9) underwent liver transplantation due to
severe cholestatic liver disease.
Developmental delay, ataxia and dysarthria were the
most commonly recorded neurological symptoms, each
occurring in all eight patients (Fig. 1). Cataplexy/epileptic
seizures and swallowing difficulties were each recorded in
6/8 (75 %) patients. Ophthalmic assessments revealed
VSGP in 5/8 (63 %) patients.
Late-infantile onset patients
The mean (SD; range) age at neurological onset in this sub-
















Neonatal (n = 6)
Early infantile (n = 8)
Late infantile (n = 51)
Juvenile (n = 42)
Adolescent/adult (n = 25)
Non neurological (n = 14)
Fig. 2 Occurrence of visceral symptoms per patient subgroup Percentages calculated based on numbers of patients with available data
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7/F – 2000 4 m 3y 4 mb PJ LD Yes C 2y
11 m
– <18 m <2y 13 m – <2y No – – c.3578_3591 +
9del/c.3578_
3591 + 9del
8/F – 2006 19 m 3y 9 mb PJ Yes No No Yes Yes 19 m – Yes No – – –
9/F – 2005 3 m 4y 1 mb PJ LD,
LTx
Yes – – Yes Yes Yes – Yes No – – c.1526A >
C(p.Tyr509Ser/?
10/F – 2003 6 m 4y 5 mb PJ LD Yes E 3y 5 m <18 m Yes Yes 3y – No
speech




11/M d 1990 PM 7y 8 mb No No C 2y E
4y
Yes <2y <2y 5y – Yes No – – c.2819C >
T(p.Ser940Leu/?a
























aSecond mutant allele not found after full genome sequencing; bPatient died; ‘–’, no data/not known; C cataplexy, E epilepsy, FA foetal ascites, HS/S hepatosplenomegaly/splenomegaly, LD liver disease, LTx liver













(SD) time period between neurological onset and diagnosis
among patients with available data was 0.56 (5.25) years.
Again, diagnostic testing was commenced in approximately
half of this patient subgroup after initial recognition of vis-
ceral symptoms.
Overall, 30/51 (59 %) patients died before data cut-off at
the end of 2011 (mean [SD] age at death 13.4 [6.7] years).
‘NP-C’ was listed as the cause of death in 26/30 patients
(87 %) with available information. Pneumonia was listed
specifically as the cause of death in two cases, but any as-
sociation with dysphagia or previous food aspiration was
not recorded.
Neurological manifestations were more common than
visceral symptoms in this subgroup (Table 4). Again, devel-
opmental delay was recorded most frequently (in all 51 pa-
tients), followed by ataxia (in 45/51 [88 %]) and VSGP (in
42/51 [82 %]). Dysarthria, dysphagia and seizures/cataplexy
were observed in 42/51 (82 %), 36/51 (71 %) and 34/51
(67 %) patients, respectively (Fig. 1).
The only two patients in the UK cohort who had
NPC2 mutations were in this age-at-onset subgroup (pa-
tients 54 and 65), both of whom displayed neonatal
jaundice and hepatosplenomegaly, as was common
among other late-infantile onset patients. However, both
of these patients displayed relatively few typical neuro-
logical manifestations: patient 54 had developmental
delay, dysarthria and dysphagia, and only developmental
delay was recorded in patient 65.
Overall, hepatosplenomegaly was the most common vis-
ceral symptom in this patient subgroup, recorded in 32/51
(63 %) patients. A history of neonatal jaundice was re-
corded in 29/51 (57 %) (Fig. 2).
Juvenile-onset patients
Among juvenile-onset patients, neurological manifestations
were first noted at a mean (SD; range) age of 9.4 (2.6; 5.0–
15.0) years. The mean (SD) time between neurological on-
set and diagnosis was 1.64 (6.09) years. In this subgroup,
diagnostic testing was commenced based on the appear-
ance of neurological signs in the majority (approximately
three-quarters) of cases.
In total, 19/42 (45 %) patients had died by data cut-off
(mean [SD] age at death, 25.9 [8.9] years) (Table 5). As for
late-infantile onset patients, most deaths (11/18 evaluable
patients [61 %]) in this subgroup were recorded as being
due to ‘NP-C’. Four of the 18 (22 %) patients with avail-
able information died due to respiratory-related complica-
tions but again, no associations with dysphagia or
previous aspiration were noted.
Neurological manifestations were substantially more
common than visceral symptoms in this subgroup. Ataxia
was the most common neurological manifestation (in 39/
42 [93 %] patients), followed by VSGP and childhood de-
velopmental delay or cognitive problems (both in 38/42
[91 %]), dysphagia (35/42 [83 %]), dysarthria (33/42
[79 %]) and seizures/cataplexy (25/42 [60 %]) (Fig. 1). Un-
like younger patient subgroups, psychiatric disturbances
were recorded in juvenile-onset patients (8/42 [19 %]
cases). The age at onset of psychiatric disturbances ranged
from 16 to 32 years.
Neonatal jaundice and/or cholestatic liver disease were
recorded in 14/42 (33 %) patients, and organomegaly was
seen in 18/42 (43 %) patients (Fig. 2). While no specific
neurological signs were recorded in one patient (patient
81), evidence of neurological involvement was docu-
mented at the local treatment centre. However, it is not
possible to report this patient’s presenting neurological
manifestation as he was lost to follow up.
Adolescent/adult-onset patients
Overall, patients with neurological onset during adoles-
cence or adulthood were characterized by insidious onset
and slow disease progression (Table 6). Neurological onset
in this older age subgroup occurred at a mean (SD; range)
age of 24.2 (8.8; 15.0–40.0) years. The mean (SD) period
between neurological onset and diagnosis was 6.0 (6.26)
years, and all evaluable patients in this subgroup were di-
agnosed after the appearance of neurological symptoms.
By data cut-off, a total of 8/24 (32 %) patients had died
(mean [SD] age at death, 33.7 [6.2] years). Among patients
with available records, seven were recorded as being due
to NP-C.
A history of developmental delay and/or cognitive
deterioration was the most frequently recorded neuro-
logical manifestation (in 21/25 [84 %] patients), followed
by VSGP and ataxia (both in 18/25 [72 %] patients).
Dysarthria, dysphagia and seizures/cataplexy were
present in 28–64 % of patients. Among those with
available information on time of onset of specific mani-
festations, the majority of neurological signs seemed to
appear during adulthood. In particular, patient 124 had
no observable neurological symptoms up until her 4th
decade of life, during which a full spectrum of charac-
teristic neurological signs as well as psychiatric prob-
lems occurred. Patient 129 had a long history of
neurological problems but no data on age at onset or
recorded details on specific neurological manifesta-
tions. Patient 132 displayed cognitive deterioration
since his twenties, but again, no information is avail-
able regarding specific neurological manifestations.
As in the juvenile-onset subgroup, psychiatric distur-
bances and/or cognitive deterioration were prominent in
the adolescent/adult-onset subgroups, recorded in a total
of nine patients (36 %). The age at onset of psychiatric dis-
turbances ranged between 17 and 40 years.
There was only one historical record of neonatal jaun-
dice in this subgroup, and organomegaly was recorded in
a total of 6/25 (24 %) patients. Splenomegaly or
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Table 4 Patients with late-infantile neurological onset (Continued)
28/M – 1994 9 m 9y 3 mb PJ LD HS C 4y E 7y 4y 1y <5y 5y – 5y No – – c.3182 T >
C(p.Ile1061Thr)/?d
29/F – 1990 9 m 9y 5 mb PJ LD No Yes <6y <6y 6y
5 m
– – – No – – c.3182 T >
C(p.Ile1061Thr)/?
30/F – 1975 8y 28yb PJ LD HS E 17y 8y 13y 5y Yes – Yes No – – c.3182 T >
C(p.Ile1061Thr)/?
31/F – 2003 3 m 8y 6 m PJ LD At
birth
E 8y 4y <4y <4y <7y – 5y Yes – – c.3182 T >
C(p.Ile1061Thr)/?d
32//M h 1989 2y 11y 2 mb PJ LD No E 6y 5 m Yes 4y Yes Yes – – No – – c.3182 T >
C(p.Ile1061Thr)/?
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C(p.Ile1061Thr)/?
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35/F – 1989 7y 16yb No At
birth
C 8y E 10y 5y 4y 4y
5 m
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C(p.Ile1061Thr)/?
36/M – 1987 8 m 12y 1 mb PJ LD At
birth
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8 m
5y 5y 5y 9y – Yes No – – c.3182 T >
C(p.Ile1061Thr)/?
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del10bp962
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Table 4 Patients with late-infantile neurological onset (Continued)
















48/F – 1982 3y 29y 4 m PJ HS at
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49a/F – 2001 12 m 10y 7 mb No S C 9y 4y 4y 4y 7y – 6y No – – c.3182 T >
C(p.Ile1061Thr)/
c.3591 + 4delA
50a/M – 2004 1y 11 m 7y 5 mb No 6 m C 4y 4y 3y
5 m




51/F i 1984 8y 6 m 27y 5 m No 2y C 5y 8y 13y 5y 13y – 11y No – – c.3467A >
G(p.Asn1156Ser)/?d
52/F i 1978 14y 5 m 33y 5 mb No No E 13y 14y 5y 13y 13y – 12y No – – c.3467A >
G(p.Asn1156Ser)/?d




4y 8y 6 m – Yes No – – c.3591 + 4delA/?d




55/M k 2000 – 10y 5 mb No No C 6y 5y 5y 5y 5y – Yes No – – –
56/M – 2005 3y 10 m – Yes – – – 4y – – – 4y No – – –






5y – No No – – –
58/M – – 9y 5 m 15yb No No C + E 5y 6y 6y 4y 10y – Yes No – – –
59/F – 1987 8y 17y 6 mb No 4y C 5y E 10y 7y 5y 6y 11y – Yes No – – –
















Table 4 Patients with late-infantile neurological onset (Continued)








10y – Yes No – – –
62/F – 1993 5y 9y 5 mb PJ HS 5y
5 m
C 5y No 18 m 4y No – Yes No – – –
63/M k 1998 – – – – – Yes Yes Yes Yes – Yes No – – –




65/F – 2008 2y 3y 9 m Yes HS No No Yes No No – No No – – [NPC2]c
aPatients included in previously reported NPC Registry baseline characteristics study [19]; bpatient died; cmutation found but information not accessible during observation period; dsecond mutant allele not found
after full genome sequencing. ‘–’, no data/not known; C cataplexy, E epilepsy, FA foetal ascites, HM hepatomegaly, HS/S hepatosplenomegaly/splenomegaly, LD liver disease, LTx liver transplant, m months, NC neonatal













































66/F – 1970 24y 5 m 41y
2 m
No Yes C 24y 12y 11y 24y 24y 32y 24y Yes 32y – c.1211G >
A(p.Arg404Gln)/?d
67/F – 1995 10y 1 m 16y
3 m




8y 10y 13y No Yes Yes 12y 4y c.1552C >
T(p.Arg518Trp)/c.283 T>
C(p.Ser95Pro)
68/F – 1996 10y 6 m 15y
1 m
– – <10y Yes <10y <10y <10y No <10y No – – c.2848G >
A(p.Val950Met)/?
69/F – 1994 14y 17y
10 m
No No No Yes 10y Yes Yes – 6y No – – c.2974G >
T(p.Gly992Trp)/?
70/F – 1983 14y 21y
11 mc
No No E 12y Yes 8y 11y 17y No Yes No – – c.3019C >
G(p.Pro1007Ala)/?
71a/M – 1991 17y 20y
4 m








E 14y 11y 11y 14y 15y No <14y No – – c.3176G >
A(p.Arg1059Gln)/?
73/M – 1996 14y 15y
5 m
No No No 12y 7y 7y 13y No 12y Yes 14y 1y c.3182 T >
C(p.Ile1061Thr)/?
74/M – – 7y 5 m 20yc PJ HS No 7y 6y 5 m 7y 8y No Yes No – – c.3182 T >
C(p.Ile1061Thr)/?
75/F – 1986 10y 19y
2 mc
No No C 11y 10y 7y 7y 11y No Yes No – – c.3182 T >
C(p.Ile1061Thr)/?
76/M – 2000 7y 11y
1 mc
– – E 7y Yes Yes Yes Yes No Yes No – – c.3182 T >
C(p.Ile1061Thr)/?








78a/F – 2002 2 m 9y
10 m

































Table 5 Patients with juvenile neurological onset (Continued)








83/F – 1991 13y 18y
2 mc




84b/M – 1988 12y 23y
7 m
No S 7 y No 11y
9 m














86/F – 2005 8w 6y 6 m PJ LD HS No Mild
6y
No No No No No Yes 4y 2y c.3182 T >
C(p.Ile1061Thr)/
c.350-351delAG
87/F – 1986 17y 25y
5 m




88/M – 1985 18y 26y
7 m




89a/F – 1994 10y 4 m 17y
9 m
No No C <4y E
<17y
<17y <10y 4 m <10y
4 m




90/F – 1983 15y 22y
8 mc








92/F b 1990 3 m 17y
2 mc
















Table 5 Patients with juvenile neurological onset (Continued)
93/F j 1998 10y 13y
6 m
No No Yes Yes Yes Yes Yes No Yes Yes 10y 3y c.3591 + 4delAla/?
94/F – 1997 10y 14y
8 mc
No No C + E 10y No <10y <10y Yes Gx No Yes No – – c.3019C >
G(p.Pro1007Ala)/
c.2464-2465insT
95/M – 1998 12y 13y
6 m
No No C 11y 11y 9y Tremor
11y
No No <5y Yes 13y 6 m –




S – Yes Yes Yes Yes Gx No 9y No – – –
97/F – 1991 16y 17y
6 mc
– – S, C Yes <15y <15y <17y No Yes No – – –
98/M – 1967 PM 25yc PJ S 2 y No Yes 11y 2y 14y 25y Yes No – – –
99/F – 1972 16y 39y
11 m










13y 13y 5 m 13y No Yes No – – –
101/F – 1963 18y 40y
3 mc




102/F n – Teens 23yc No No – No Teens Teens Teens 23y – No – – c.3182 T >
C(p.Ile1061Thr)/?
103/M – 1987 20y 24y
5 m




104/M – 1972 6y 39y
8 m




105/M – 1969 Early 20s 37y
8 mc
PJ S 4y E 30y Yes 11y 20s Yes No Yes No – – –
106a/F o 1976 27y 35y
10 m




107/M o 1972 30y 37y
2 mc




aPatients included in previously reported NPC Registry baseline characteristics study [19]; bPatients included in previously reported NPC Registry baseline and longitudinal data study [19, 20]; cpatient died; dsecond
mutant allele not found after full genome sequencing. ‘–’, no data/not known; C cataplexy, E epilepsy, FA foetal ascites, Gx gastrostomy, HM hepatomegaly, HS/S hepatosplenomegaly/splenomegaly, LD liver disease, LTx




















































11/M – 1978 20y 27y 3 mc No No No <24y <20y No 23y Yes – No – – –
111/F – 1975 25y 6 m 30yc No No C 25y 25y 16y 24y 23y No 23y No – – –
112/M n 1971 24y 40y 2 m No No No 16y 24y <24y No 29y 32y No – – c.3182 T >
C(p.Ile1061Thr)/?




114a/M – 1987 22y 24y 11 m No No No 22y 15y 15y 23y No 18y Yes 24y 0.5y –












118/M – – 27y 35y 4 m – Yes Teens No Yes Yes Yes 20s Yes No – – –
119d/F – 1966 32y 42y No No No Yes <18y 29y 38y No 38y Yes 37y 8 c.3182 T >
C(p.Ile1061Thr)/?
120/M – 1972 29y 39y 10 mc – – – – Yes – – – – No – – –
121a/M – 1982 20y 29y 2 m No No No – Yes – – – Yes No – – –
122/M – 1964 31y 48y 6 m No Yes No Yes 46y No Yes No No Yes 42y 5y –
123a/M q 1967 40y 44y 5 m – No Tremor <40y <40y <40y No No No Yes 43y 1y c.1408G >
C(p .Ala 470 Pro/
c.1816G >
C (p.Glu608Gln)














Table 6 Patients with adolescent-adult neurological onset (Continued)












128/F – 1954 49y 6 m 57y 6 m No No No Yes Yes 20s No No 20s No – – c.3182 T >
C(p.Ile1061Thr)/?




130/M q – 40y 41y 9 m – 40y Tremor (35y) Yes No Yes 40y No No Yes 39y – c.1408G >
C(p .Ala 470 Pro/
c.1816G >
C (p.Glu608Gln)








aPatients included in previously reported NPC Registry baseline characteristics study [11]; bPatients included in previously reported NPC Registry baseline and longitudinal data study [11, 12]; cpatient died; dpatient
119 F previously subject of case report by Lachmann et al. [10]; etreatment interrupted (first treatment start at 39 y, second treatment start at 46 y); ‘–’, no data/not known; C cataplexy, E epilepsy, FA foetal ascites, HM













hepatosplenomegaly were observed in three patients dur-
ing adulthood (at age 18–40 years; patients 113, 125 and
130), and splenomegaly was recorded during the neonatal
period in one patient (patient 115 at age 16 months).
Patients with no neurological manifestations
There were a total of 14 patients who had not displayed
any neurological manifestations by data cut-off (Table 7).
Genetic analyses have revealed NPC1 mutations in the
majority (n = 10; 71 %) of these patients, confirming NP-
C. Diagnoses among those without identified gene muta-
tions were confirmed based on filipin staining. All of these
patients had at least one early visceral symptom of NP-C:
neonatal liver disease (mostly prolonged jaundice) and
organomegaly both occurred in 11/14 (79 %) patients in
this subgroup. Two patients (141 and 143) died in their
2nd and 3rd decades of life due to non NP-C related
causes, and patient 146 died aged 4 years due to liver can-
cer. The remainder of non-neurological patients were alive
at data cut-off. The mean (SD) age at last follow up prior
to data cut off was 2.5 (1.8) years (range 0.5–6.1 years; n =
11). Among the three patients who died, mean age at
death was 20.8 (15.9) years (range 4.9–36.7).
Genetics
Overall, 116/146 (79 %) patients had at least one identified
NP-C gene mutation (Tables 2–6). Two mutations were
recorded in 78/146 (53 %) patients and one mutation was
recorded in 38/146 (26 %) patients. Most patients (98 %)
with recorded mutant alleles had NPC1 mutations, and
two patients (2 %) had NPC2 mutations (one with homo-
zygous c.58G > T(p.Glu20X) mutant alleles and one with a
single identified mutation for which information was not
available). Thirty patients (21 %) had no recorded infor-
mation regarding identified NP-C gene mutations. This
number may be reduced in future with the increasing
availability of next-generation sequencing methods.
Amongst a total of 194 identified mutant NP-C gene al-
leles, 53 have been classified as novel mutations. The com-
mon I1061Thr mutation was recorded in a total of 55
(38 %) patients in the whole cohort (heterozygous in 89 %
and homozygous in 11 % of cases). Among the age-at-
neurological onset subgroups, I1061Thr mutant alleles
were mainly observed in patients with the late infantile-
(23/51 [45 %]) and juvenile-onset forms (18/42 [43 %]). A
lower proportion of patients in the adolescent-adult onset
group had this mutation (7/25 [28 %]). However, the preva-
lence of I1061Thr mutations was particularly high among
non-neurological patients (n = 7 [50 %]; six heterozygotes
and one homozygote). One patient with a I1061Thr allele
(patient 73), also had a c.882-40 T >A mutant allele, and
family studies detected this genotype in the child’s father.
However, it is not currently known if the c.882-40 T >A al-
lele is a pathogenic mutation.
Eight patients with available genetic information had
the p.Pro1007Ala mutation. Cases were fairly evenly dis-
tributed between the late-infantile, juvenile and adoles-
cent/adult-onset subgroups.
Full genome sequencing performed in a number of
patients with one identified mutation failed to detect
any second mutation. These patients (and their listed
genotypes) were: 11 (c.2819C > T(p.Ser940Leu/?), 18
(c.2008_2011del(p.Cys670ProfsX17/?), 28 (c.3182 T >
C(p.Ile1061 Thr)/?), 31 (c.3182 T > C(p.Ile1061Thr)/?),
51 (c.3467A > G(p.Asn1156Ser)/?), 52 (c.3467A >
G(p.Asn1156Ser)/?), 53 (c.3591 + 4delA/?) and 66
(c.1211G > A(p.Arg404Gln)/?).
Miglustat use
The information regarding miglustat use should be regarded
in recognition of the year during which miglustat became
commercially available in the EU (2009), and of the time of
data cut-off. Overall, 51 patients (35 %) received miglustat
during the observation period (Tables 2–6): 2/8 (25 %) early
infantile-onset patients and 17/51 (33 %), 20/42 (48 %) and
12/25 (48 %) patients in the late infantile-, juvenile-, and
adolescent/adult-onset subgroups, respectively. No patients
with the neonatal form of NP-C and no patients in the
‘non-neurological’ subgroup received miglustat.
The mean ages at treatment start ranged from 0.5 to
49.0 years across the age-at-onset subgroups. Among a
total of 38 patients with evaluable information on treat-
ment duration, the overall estimated mean (SD) treatment
duration was 2.6 (2.3) years: median (range) 2.0 years
(1 week to 8 years). Approximate mean (SD) durations
per evaluable age-at-onset subgroup were: 2.6 (2.0) years
in late infantile-, 2.8 (2.4) years in the juvenile-, and 2.9
(2.6) years in the adolescent/adult-onset subgroups.
Disease course among related patients
A total of 44 patients from 20 families in this cohort were
siblings, most of whom (38 [86 %]) had at least one identi-
fied NPC1 mutant allele (see Additional file 1: Table S1).
No NP-C gene mutations were identified in three sibling
pairs: diagnoses were established by other means based on
clinical symptoms and/or laboratory biochemical (filipin
testing) and histological methods.
In general, ages at neurological onset and clinical phe-
notypes appeared congruent between siblings with identi-
cal mutant genotypes. Exceptions included patient 6, the
sister of patients 25 and 26, all of whom were homozygous
for the c.3020C > T (p.Pro1007Leu) mutant allele. Patient
6 had the neonatal-onset form of NP-C, neonatal liver dis-
ease and hepatosplenomegaly, and died aged 2 months
due to failure to thrive and severe chest infection. Her sis-
ters are twins and have late-infantile onset NP-C. Both
twins also had neonatal jaundice and hepatosplenomegaly,
with a variety of characteristic neurological signs observed
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133/M – 2010 4 m 6 m Yes No No No No No No No – –
134/M – 2010 8 m 8 m Yes – – – – – – – – c.3182 T > C(p.Ile1061Thr)/?
135/M – 2010 1y 1y Yes (LTx) Yes No No No No No No No –
136/M – 2006 6 m 2y 5 m PJ LD <4y No No No No No No No c.3182 T > C (p.Ile1061Thr)/
c.3182 T > C (p.Ile1061Thr)
137/M – 2003 2y6m 6y 1 m No Yes No No No No No No No c.3182 T > C (p.Ile1061Thr)/
c.3467A > G (p.Asn1156Ser)
138/M – 2009 4 m 2y 1 m PJ LD Yes No No No No No No No c.3182 T > C (p.Ile1061Thr)/?
139/M t 2010 <1y 1y Yes Yes No No No No No No No c.3182 T > C (p.Ile1061Thr)/
c.3289G > A (p.Asp1097Asn)
140/M t 2006 – 5y No No No No No No No No No c.3182 T > C (p.Ile1061Thr)/
c.3289G > A (p.Asp1097Asn)
141/F s 1971 1y5m 36y 8 ma PJ LD Birth No No Yes No No No No c.2336del (p.Phe779SerfsX2)/
c.2621A > T (p.Asp874Val)
142/F – 2008 2y5m 3y Yes Yes No No No No No No No c.3182 T > C (p.Ile1061Thr)/
c.3259 T > C (p.Phe1087Leu)
143/M – 1987 16y 20y 10 ma PJ Birth No No No No No No No c.2621A > T (p.Asp874Val)/
c.3591 + 4 delA
144/M – 2007 1y9m 4y No Yes No No No No No No No –
145/M – 2009 4 m 2y Yes Yes No No No No No No No –
146/F – 2004 7 m 4y 11 ma PJ Yes No No No No No – No c.3083-
3084delP.Gly1028AlafsX22)/
c.2201G > T(p.Ser734Ile)
aPatient died; ‘–’, no data/not known; HS/S hepatosplenomegaly/splenomegaly, LD liver disease, LTx liver transplant, m months, PJ prolonged jaundice, y years, w weeks. Note that none of the non-neurological patients













from before the age of 4 years, but both were still alive at
the time of data cut-off.
Another sibling pair (patients 80 and 108) were both
heterozygotes with c.3182 T > C (p.Ile1061Thr) and
c.3019C >G (p.Pro1007Ala) mutant alleles. The older sib-
ling (patient 108) has adolescent/adult-onset NP-C, pre-
sented with VSGP, developmental delay and psychiatric
disturbances in his late-teens, and survives aged 39 years
at last follow up: he had received miglustat therapy for
3 years at data cut-off. His brother (patient 80) had
juvenile-onset NP-C and presented with developmental
delay and VSGP before 10 years of age. He also had severe
seizures that are considered likely to have contributed to
his death ‘due to NP-C’ at the age of 18 years.
Finally, patients 139 and 140 both have no neurological
manifestations. While patient 139 was diagnosed at an
early age following investigations of neonatal liver disease
and organomegaly, his older brother has no record of
systemic manifestations, and was diagnosed (based on
genetic testing) due to mainly to his sibling disease
history.
Discussion
It is important to continue gathering knowledge on the
natural history of NP-C in order to aid in the clinical
management and targeted therapy of affected patients,
and to aid in providing counselling and support for their
families and caregivers. This summary of data from 146
historical and current UK-based NP-C patients analysed
between 1999 and end-2011 provides findings from the
largest national NP-C cohort reported to date. Although
some patients have minimal data available, they are still
included in this report to indicate the full extent of the
UK NP-C cohort and provide as full a clinical picture of
diagnosed patients as possible.
Based on recent estimates of the total UK population
(64.1 million) and national birth rate (12.27/1000) the
current birth prevalence of NP-C in the UK is 0.78 cases
per 100,000 births, which seems roughly in line with
previous estimates of birth prevalence of NP-C in West-
ern Europe (France, Germany and the UK) over the
period 1988–2002 [21, 22]. Based on records of all
known UK cases diagnosed since 1985, the rate of diag-
noses per decade (i.e., the mean number across all years
within each decade) has risen steadily over the last three
decades, from 3.5 new cases/year during 1985–1994 to
5.1 new cases per year during 1995–2004, and 6.0 new
cases per year during 2005–2011. In addition, a total of
21 new cases have been diagnosed between 2012 and
2015, although these most recent cases are not included
in this cohort analysis due to non-availability of access
to full clinical information after data cut-off. This trend
possibly reflects increased awareness of the disease over
the last two decades and, in particular, improvements in
genetic analysis methods for confirmation of disease-
causing mutations.
Data on visceral symptoms in this cohort were in line
with baseline data from 163 patients included in the Inter-
national NP-C Registry [19]. Neonatal liver disease and/or
prolonged jaundice, or a history of just neonatal jaundice,
was a feature in all age subgroups in this cohort. As could
be expected, neonatal jaundice was recorded in many pa-
tients (50–100 %) in the infantile-onset subgroups, and in
far lower proportions of patients (0–33 %) in the juvenile-
and adolescent/adult-onset subgroups. There was a clear
trend for decreased occurrence of organomegaly with in-
creasing age at neurological onset, although organomegaly
was not as common in the neonatal-onset subgroup as it
was among early-infantile onset patients due to its incre-
mental nature. Nevertheless, splenomegaly is generally
considered a consistent indicator of possible NP-C in neo-
nates, and has often served as a signal leading to early
diagnosis.
NP-C has been reported as the second most common
genetic cause of liver disease during infancy in the UK,
after alpha-1-antitrypsin deficiency [23, 24], and investiga-
tions to exclude NP-C are common practice in liver dis-
ease/neonatal units. A large proportion of early-onset
patients in this cohort underwent extensive liver investiga-
tions during the neonatal period, but in many cases NP-C
was subsequently diagnosed years later, after the appear-
ance of neurological signs. This seems typical of the NP-C
population as a whole, as reflected by substantial delays to
diagnosis in many cases, globally, and reflects the need for
clinicians in all specialities to take a full clinical history
when seeing new patients.
Based on previous clinical observations, neonatal jaun-
dice without other overt signs of liver disease can herald a
more aggressive clinical course of NP-C, particularly if
neurological abnormalities appear during the first 4 years
of life [15, 24]. However, the degree of neonatal liver dis-
ease does not appear to be a reliable indicator of future
disease progression, as illustrated by cases where neuro-
logical manifestations became apparent during adulthood
despite a history of neonatal liver disease. It is important
to consider that early visceral symptoms lack prognostic
value in NP-C during family counselling for NP-C cases
diagnosed during the neonatal period, providing advice
for planning ahead for the emotional and financial bur-
dens of the disease [25]. Of particular note are the sibling
patients 132 and 141, who share identical novel heterozy-
gous NPC1 mutations. Both had very severe neonatal liver
disease necessitating intensive care, and were followed up
over a course of years by their hepatologist. Patient 141
had non-neurological NP-C and died at the age of 36 due
to a severe infection in late pregnancy: post-mortem
examination showed no storage or neurological problems.
Her brother (patient 132) was still alive and self-caring at
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data cut off, and displayed mild cognitive impairment at
last follow up.
The profile of neurological manifestations recorded in
this cohort was consistent with other large-cohort NP-C
studies [2, 4, 16, 19, 26], with over half of patients display-
ing one or more of: ataxia; VSGP; dysarthria; dysphagia;
and seizures/cataplexy. In terms of age at neurological on-
set, two-thirds of patients fell into the late infantile-onset
and juvenile-onset subgroups. Given the frequency of
childhood-onset forms of NP-C in this UK cohort up to
the end of 2011, it is not surprising that developmental
delay or cognitive deterioration were the most frequently
recorded neurological manifestations. Similarly, the
frequency of seizures and/or cataplexy was reflective
of the overall young age at onset among UK patients,
as seizure activity has generally been reported most
frequently among patients with late-infantile and
juvenile-onset disease [1].
It is notable that ataxia, which is a central component of
the recently developed NP-C suspicion index (SI) for the
detection of NP-C among patients with suggestive clinical
symptoms [9], was the second-most common neurological
manifestation in this cohort. VSGP is recognised as one of
the earliest signs of neurological deterioration in NP-C [1,
9, 27, 28], so it is unsurprising that this neurological sign
was also common. Excluding neonatal cases, VSGP was
observed in over half of all UK patients, and was most fre-
quent in those with the juvenile-onset (classical) form of
NP-C.
Psychiatric manifestations were only recorded in patients
in the juvenile and adolescent/adult-onset subgroups,
which is in agreement with previous screening data [29]
and numerous other published findings [1, 2, 30–34]. While
little information was available on the precise types of
psychiatric disorders for this analysis, patients with
juvenile-onset NP-C tend to manifest behavioural prob-
lems, impaired learning, and expressive language disorder,
which often culminate in failure at school [1]. Patients with
adolescent/adult-onset NP-C and psychiatric disorders
often exhibit schizophrenia-like psychosis (in up to 25 % of
cases), but can also be diagnosed with bipolar disorder, de-
pression and obsessive-compulsive disorder [1, 34].
While the severe neonatal and early-infantile onset
forms of NP-C resulted in rapid deterioration and early
mortality in the current cohort, total mortality decreased
with increasing age at neurological onset among the
late-infantile (59 %), juvenile (45 %) and adolescent/
adult-onset (32 %) subgroups. Mean age at death values
reflected this trend. Some adolescent/adult-onset pa-
tients have survived into their fifth and sixth decade of
life, which confirms the more insidious, mild course of
neurological deterioration that has been reported before
among adults with NP-C [1, 26]. Indeed, a recent case
has been reported of a 66 year-old female who remains
free of any neurological or psychiatric manifestations
18 years after initial presentation [35].
Wide genetic variability coupled with a high degree of
phenotypic heterogeneity make genotype–phenotype cor-
relations difficult in NP-C. Variable clinical phenotypes
have even been observed in monozygotic twins with the
same genetic mutation [36]. Overall, 53/194 (27 %) muta-
tions identified in this cohort were classified as novel. The
exon 21 (p.I1061Thr) mutant allele of NPC1 has previ-
ously been associated with the common juvenile-onset
form of the disease, and is associated with a relatively well
characterised cellular function and biochemical phenotype
[37–39]. The overall prevalence of this allele has been
quoted as approximately 15 % [21], although more re-
cently it has been reported as particularly frequent (in 20–
25 % of diagnosed cases) in France and the UK [2]. Based
on this cohort update, the p.I1061Thr mutant allele was
present in 38 % of patients overall, occurring in approxi-
mately equal proportions of patients in the late-infantile
and juvenile-onset subgroups. The incidence of the sec-
ond most frequent known NPC1 mutation – p.1007Ala –
appeared relatively much lower, occurring in the heterozy-
gous state in only eight patients overall. The prevalence
range for p.1007Ala alleles among the late-infantile, juven-
ile and adolescent/adult-onset subgroups was 4–10 %.
Interestingly, the prevalence of p.I1061Thr mutations
was particularly high in the non-neurological subgroup,
where it occurred in 50 % of patients. This begs the ques-
tion of whether some patients currently in the non-
neurological group might progress to develop neurological
manifestations in the future. For instance, ‘non-neuro-
logical’ patient 136 had no neurological symptoms at last
documented follow up aged 2.5 years. However, other pa-
tients with homozygous p.I1061Thr mutations (patients
46 and 81–84) all had late-infantile or juvenile onset
neurological symptoms. In the same way, many patients
with heterozygous p.I1061Thr mutations developed
neurological symptoms during the late-infantile period
(up to 6 years of age, n = 21), the juvenile period (n = 14),
or during adolescence/adulthood (n = 7). Further follow-
up might therefore result in re-categorisation of some or
all of the ‘non-neurological’ p.I1061Thr patients as having
symptomatic neurological disease. Nevertheless, the same
cannot be said for eight patients in the non-neurological
group in whom p.I1061Thr mutations have been ex-
cluded, and/or in whom no known NPC1 mutant alleles
have been detected.
Substrate reduction therapy (SRT) using miglustat has
been shown to be effective in treating adult patients with
Gaucher disease [40–44], and subsequently in the treat-
ment of progressive neurological manifestations in chil-
dren and adults with NP-C [1, 28, 45–48]. In total 34 % of
UK patients have received miglustat therapy for any
period of time. Longitudinal analyses of serial clinical
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status assessments are required to determine the impact
of miglustat on neurological disease progression in this
cohort.
Conclusions
In summary, the prevalence of NP-C in the UK is in line
with previous observational data from other European
cohorts, and it is notable that the annual rate of diagno-
sis of the condition has increased over the past 30 years,
possibly due to increasing awareness and improvements
in molecular diagnostic methods. The wide phenotypic
variability and the overall profile of genotypes detected
among UK patients are also consistent with data from
other Western populations. In particular, age at onset of
neurological manifestations once more appeared associ-
ated with more rapid disease progression and a lower
age at death. Further analyses are required to assess the
impact of miglustat therapy on neurological disease
progression.
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